Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe

NAMUR, Belgium, April 27, 2017 /PRNewswire/ -- Volition (NYSE MKT: VNRX) has commenced its first study in Asia - an evaluation of the Nu.Q^TM Colorectal Cancer Triage product in a Taiwanese population of 383 subjects. The study is being conducted with Professor Chiu Han-Mo of the National Taiwan University Hospital and is expected to be completed within the coming months.

"We are pleased to be working with Professor Chiu Han-Mo and hope to develop a long-term working relationship," stated Dr Jasmine Kway, Volition's Vice President of Asia 'This is an exciting time for Volition as we start our first clinical work in Asia. In addition, we are also taking our first regulatory steps in Asia as we prepare the submission of our CE Marked Nu.Q^TM Triage product to the Singapore and Taiwan regulatory authorities. Regulatory approval in Singapore and Taiwan would not only make our product saleable in these countries but also potentially in nine other South East Asian markets."

An interview with Dr Kway can be viewed at http://volitionrx.com/news/video-gallery

In Europe, Volition has received Ethical Approval to proceed with the second and final phase of the logistics and pathway design study in Denmark for its Nu.Q^TM Triage Test. The study, conducted in collaboration with the Hvidovre Hospital and The Danish Research Group on Early Detection of Colorectal Cancer, deals with the practical issues of how the product fits into Denmark's current national screening program. Results from the study are expected by the end of the third quarter this year and will be presented to the National Screening Committee.

Volition's Chief Marketing and Communications Officer, Louise Day commented "We are delighted to receive this timely Ethical Approval for the second phase of the logistics and pathway study. We are hopeful that our collaborators in Denmark will determine the very practical logistics of putting into practice the Nu.Q^TM Triage Test and provide a smooth, patient-friendly implementation into the Screening Program."

In case you missed it - a video of the Opening of our new custom-designed Research & Development facility can be found at http://volitionrx.com/news/video-gallery

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics^®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx  
Facebook: https://www.facebook.com/VolitionRx/  
YouTube: https://www.youtube.com/user/VolitionRx 

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics^®, NuQ^®, Nu.Q^TM and HyperGenomics^® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

SOURCE VolitionRx Ltd